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Abstract 
Although the natural flavonoid fisetin (3,3',4',7-tetrahydroxyflavone) has been recently 
identified as an anticancer agent with antiangiogenic properties in mice, its in vivo 
pharmacokinetics and metabolism are presently not characterized. Our purpose was to 
determine the pharmacokinetics and metabolism of fisetin in mice and determine the 
biological activity of a detected fisetin metabolite. After fisetin administration of an 
efficacious dose of 223 mg/kg i.p. in mice, the maximum fisetin concentration reached 2.5 
µg/ml at 15 min and the plasma concentration declined biphasically with a rapid half-life of 
0.09 h and a terminal half-life of 3.1 h. Three metabolites were detected, one of which was a 
glucuronide of fisetin (M1), whereas another glucuronide (M2) was a glucuronide of a 
previously unknown fisetin metabolite (M3). HPLC MS/MS analysis indicated that M3 was a 
methoxylated metabolite of fisetin (MW=300 Da). The UV spectrum of M3 was identical to 
that of fisetin and standard 3,4',7-trihydroxy-3'-methoxyflavone (geraldol). In addition, 
because M3 co-eluted with standard geraldol in 4 different chromatographic ternary gradient 
conditions, M3 was therefore assigned to geraldol. Of interest, this metabolite was shown to 
achieve higher concentrations than fisetin in Lewis lung tumors. We also compared the 
cytotoxic and antiangiogenic activities of fisetin and geraldol in vitro and it was found that the 
latter was more cytotoxic than the parent compound toward tumor cells, and that it could also 
inhibit endothelial cells migration and proliferation. In conclusion, these results suggest that 
fisetin metabolism plays an important role in its in vivo anticancer activities. 
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1.  Introduction 
Among the numerous products available from plants, the flavonoid superfamily plays 
a central role by their interesting pharmacological properties for several diseases, including 
cancer prevention and therapy [1-4]. We, and others, have recently identified fisetin (3,3',4',7-
tetrahydroxyflavone, Figure 1), a flavonoid found in several fruits, vegetables, nuts and wine 
[5;6], as a lead compound possessing biological properties of potential interest in the 
prevention and/or treatment of cancer in vivo [7-9]. Fisetin possesses antioxidant and anti-
inflammatory activity [10;11] and was found to be cytotoxic and antiangiogenic in vitro 
[12;13]. Fisetin is cytotoxic to various human cancer cell lines including leukemia (HL60) 
[14], breast (MCF7) [13], colon (HT29) [15], liver (SK-HEP-1, Caco-2) [15;16], 
neuroblastoma (SHEP, WAC-2) [13], prostate (LNCaP, PC3) [17], and also to endothelial 
cells [13]. Fisetin appears to interact with several molecular targets, including cyclin-
dependent kinases [18-20], DNA topoisomerases I and II [21;22], urokinase [23], actin [24], 
and androgen receptor signaling [7]. It has also recently been found that fisetin induces a 
forced exit from mitosis by targeting the mitotic spindle checkpoint involving the inhibition 
of Aurora B activities required for the maintenance of normal spindle checkpoint signaling 
[25]. In vivo, fisetin has shown antiangiogenic activity after topical application in a rabbit 
model of corneal neovascularization [26]. After systemic administration in mice, fisetin has 
shown interesting antitumor activity in several cancer models, including prostate, 
teratocarcinoma and lung carcinoma [7-9].  
Although fisetin has shown activity in vitro and in vivo in mice, there is presently no 
information concerning the fisetin levels achieved in this preclinical species that could allow 
in vitro and in vivo comparisons. Moreover, the fisetin molecule bearing 4 hydroxyl 
substituents, including a catechol on the phenyl B ring, is therefore probably extensively 
metabolized in vivo. In the present study, at an effective dose of 223 mg/kg given by the i.p. 
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route, we were therefore interested to determine the pharmacokinetics and metabolism of 
fisetin in vivo in mice.  
We report here the pharmacokinetics of fisetin and its main metabolites in mice. In 
addition to glucuronide conjugates, we identified a 3’-methoxylated metabolite of fisetin 
(3,4',7-trihydroxy-3'-methoxyflavone or geraldol) as a major metabolite of fisetin. This 
methoxylated metabolite was found to be more cytotoxic that the parent compound and could 
also inhibit endothelial cells migration and proliferation.  
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2.  Materials and Methods 
 
2.1. Chemicals and reagents 
Fisetin (3,3',4',7-tetrahydroxyflavone), kaempferol (3,4’,5,7-tetrahydroxyflavone), β-
glucuronidase, dimethylsulfoxide (DMSO), polyethylene glycol 200 (PEG200) were 
purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France), and geraldol (3,4',7-
trihydroxy-3'-methoxyflavone) was obtained from Extrasynthese (Genay, France). For HPLC 
studies, stock solutions of fisetin, kaempferol and geraldol were prepared in methanol and 
stored at -20°C protected from light. Methanol (HPLC grade) was purchased from Carlo Erba 
(Val de Reuil, France), glacial acetic acid was from Prolabo (Paris, France), and water was 
purified using a Milli-Q apparatus from Millipore Corporation. For cell culture, stock 
solutions of fisetin and geraldol were freshly prepared in DMSO and further diluted in cell 
culture medium. Matrigel and bFGF were obtained from BD Biosciences (Le Pont de Claix, 
France). All other chemicals were obtained from commercial sources and were of the highest 
purity available. 
 
2.2. Fisetin pharmacokinetics in mice 
Female 8 weeks old C57BL/6J mice (mean body weight 18-22 g), were purchased from 
Janvier (Le Genest-St-Isle, France). After an overnight fasting period, mice were injected 
intraperitonelly (i.p.) with fisetin (223 mg/kg body weight) dissolved in 100 µl of 
PEG200/DMSO (7:3; v:v). This dose level was chosen because it was non toxic (based on 
body weights) when administered i.p. (daily X 5) for 2 consecutive weeks and also because 
this dose was found active in Lewis lung carcinoma bearing mice [9]. Blood samples (n=3 per 
sampling time) were collected by cardiac puncture with heparinized syringes after sacrificing 
the animals by CO2 at the following times: pre-administration (time 0), and at 0.25, 0.5, 1, 
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1.5, 2, 4, 8, 15 and 24 h post-dosing. Blood samples were transferred into polypropylene tubes 
and centrifuged at 12,000g for 10 min to obtain the plasma which was kept at -20°C until 
HPLC analysis. For the determination of fisetin and metabolites in tumors, pieces of Lewis 
lung carcinoma (LLC) were injected subcutaneously into the right flank of female C57BL/6J 
mice (5 mm
3
) on day 0. Fifteen days later, when the tumors reached a volume of 500-1000 
mm
3
, mice were injected with fisetin (223 mg/kg, i.p.) dissolved in 100 µl of polyethylene 
glycol 200/DMSO (7:3; v:v), and 15 min later, the mice were sacrificed and the tumors were 
harvested, rinsed with ice-cold PBS and transferred into a polypropylene tube and kept at -
20°C until analysis. All animal experiments have been carried out in accordance with 
institutional and French regulations concerning the protection of animals used for 
experimental and other scientific purposes, and with the European Commission regulations.  
 
2.3. Sample preparation and extraction 
Plasma samples, tumor or normal tissues homogenates (prepared with 1 ml of PBS using a 
Teflon potter at a speed of 50 rpm with 3 strokes), were extracted by mixing (Vortex mixer, 1 
min) with a 5-fold volume of cold methanol containing kaempferol (3,4’,5,7-
tetrahydroxyflavone, Fig. 1), as an internal standard (final concentration 3.3 µg/ml). The 
mixture was put on ice for one hour to precipitate the proteins, and the samples were 
centrifuged at 12,000g for 10 min at 4°C. The upper phase was transferred to another 
polypropylene tube and 100 µl was injected onto a Shimadzu HPLC-UV system described 
below.  
 
2.4. Standard curves and extraction 
Stock solutions of fisetin, geraldol and kaempferol (cf., Fig. 1) were prepared in methanol at 
100 µg/ml and stored at -20 °C in the dark. Working standard solutions of increasing 
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concentrations of fisetin and geraldol were prepared on the day of analysis by diluting the 
stock solution. The standard curves of fisetin and geraldol in mouse plasma, tumors, or 
normal tissues, were built using the ratio of the area of fisetin or geraldol over the area of the 
internal standard (kaempferol) and were linear within the concentration range used (0.01 to 20 
µg/ml) with correlation coefficient >0.99. The percent extraction from plasma, tumors, or 
normal tissues was 91% and the lower limit of quantification was 0.01 µg/ml. The apparent 
concentration of the metabolites was calculated based on the fisetin standard curve. 
 
2.5. HPLC system for pharmacokinetic studies 
For pharmacokinetic studies we used a HPLC-UV system (Shimadzu CLASS-VP
®
, version 
5.3), equipped with a C18 column (Beckman Ultrasphere ODS, 5 µm; 4.6 × 25 mm) 
thermostated at 20°C, and a UV detector set at 360 nm. The mobile phase was composed of 
52% methanol, 48% aqueous acetic acid (2%), at a flow rate of 1 ml/min.  
 
2.6. Pharmacokinetic parameters determination 
Fisetin plasma concentrations were analyzed using non compartmental analysis and also using 
a bicompartmental model with extravascular administration. The following non 
compartmental pharmacokinetics parameters were derived using standard methods [27]: area 
under the plasma concentration versus time curve from time zero to the time of the last 
measurable concentration (AUC0-t) calculated by the trapezoidal method; maximum 
concentration (Cmax); mean residence time (MRT); terminal half-life; apparent intraperitoneal 
clearance (CL/F) and volume of distribution at steady state (Vss/F). Pharmacokinetics 
parameters were also determined by fitting the fisetin plasma concentration versus time to a 
two-compartmental model with extravascular administration using the Graph Pad Prism 
software.  
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2.7. Identification of metabolites 
 
2.7.1 Hydrolysis of glucuronide conjugates. To hydrolyze glucuronide conjugates, plasma 
or tumor homogenate samples were adjusted to pH 5.0 with an equal volume of 50 mM 
acetate buffer, and incubated at 37°C for 2 h in the presence of 1000 units of β-glucuronidase 
(Sigma No. G-0751). The hydrolyzed samples were submitted to the above described protocol 
of methanolic extraction and injected onto the HPLC system. 
 
2.7.2 Identification of metabolite M3 using UV and mass spectrometry. Metabolite M3 
was analyzed online using an HPLC-MS/MS system composed of an HPLC apparatus 
(Surveyor

, ThermoElectron) equipped with a UV diode array detector and coupled with a 
mass spectrometer (LCQ-Advantage

, ThermoElectron). A C18 reversed-phase column (EC. 
250/2 Nucleodur Sphinx RP, 5 µm, 250 mm X 2.1 mm, Macherey-Nagel) thermostated at 
30°C was used. The metabolites (injection volume: 15 µl) were resolved with the following 
ternary gradient using methanol (A), acetonitrile (B) and aqueous 0.1% TFA (C) at a flow rate 
of 0.2 ml/min: from 0 to 50 min, 7-35% A, 4-19 % B, 89-46 % C; from 50 to 60 min, 35% A, 
19% B, 6% C (gradient 1). The mass spectrometer consisted of an electrospray ionization 
system used in positive ion polarity mode and ion trap mass analyzer. The operating 
parameters where as follows: the spray needle voltage was set at 4.0 kV and the spray was 
stabilized with a nitrogen sheath gas. Electrospray capillary voltage was 4.0 V, nitrogen was 
used as auxilliary gas, and the capillary temperature was 250°C. The Xcalibur
®
 software was 
used for data acquisition and analysis. 
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2.7.3 Identification of M3 using retention times in various gradient systems. To ascertain 
the identity of M3, this metabolite and authentic geraldol were separately injected using the 
HPLC system with gradient 1 described in section 2.7.2, and three other ternary gradients 
composed of methanol (A), acetonitrile (B) and aqueous 0.1% TFA (C) (flow rate 0.2 ml/min) 
as follows: gradient 2- from 0 to 70 min, 7-35% A, 4-19% B, 89-46% C; gradient 3- from 0 to 
50 min, 15-35% A, 10-19% B, 75-46% C; gradient 4- from 0 to 70 min, 15-35% A, 10-19% 
B, 75-46% C. For each gradient, the logarithm of the retention factor (log k) of M3 and 
geraldol were calculated using retention time and dead time. The retention factor relates to 
retention time, but is preferred because it is dimensionless and independent of unexpected 
variations in mobile phase flow. In contrast to retention time, the log k can unequivocally be 
ascribed to structural changes, as previously used for flavonoids by Stefova et al., 2007 [28]. 
To further ascertain the identity of M3, we also injected an equimolar mixture of geraldol and 
M3 using all 4 gradient systems.  
 
2.8. In vitro cytotoxic activity of fisetin and metabolite 
The murine Lewis lung carcinoma (LLC) cell line, the normal NIH 3T3 murine fibroblast cell 
line and the EAhy 926 endothelial cell line were grown in Dulbecco's modified Eagle's 
medium (DMEM) containing 2 mM L-glutamine, 10% fetal bovine serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin (37°C, 5% CO2). Exponentially growing cells were 
plated onto 96-well plates at 5000 cells per well in 200 µl. Twenty-four h later, cells were 
exposed for 24 or 48 h to fisetin or geraldol at increasing concentrations (0 to 1 mM). 
Viability was assessed using the MTT test and absorbance was read at 562 nm in a microplate 
reader (BioKinetics Reader, EL340). Appropriate controls with DMEM only and MTT were 
run to subtract background absorbance. Experiments were run in quadruplicate and repeated 3 
times. Control cells were exposed to 1% DMSO which was not cytotoxic. The results are 
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presented as the inhibitory concentrations for 50% of cells (IC50) for a 24 or 48 h exposure 
time relative to controls. 
 
2.9. Cell migration assay (scratch wound assay) 
EAhy 926 endothelial cells were grown to confluence and a wound was introduced by 
clearing an area of the monolayer using a 100 µl pipet tip. After wounding, digital 
photographs were recorded of wounded areas of each well at a magnification of X 100 (time 0 
h). Medium was changed, and bFGF (10 ng/ml), fisetin or geraldol was added at increasing 
concentrations (0, 22, 44 and 88 µM) to the media containing 2.5 % of FBS. After a 24 h 
incubation period, digital photographs were recorded of the cleared areas of each well. 
Migration was evaluated by manually drawing the distance of the wound area (d) at T0h and 
T24h time on a computer screen and distances values were obtained using the ImageJ software 
[29]. The results were expressed as a percent of the controls using the following formula: 100 
× [1-(dT0h-dT24h of treated cells)/( dT0h-dT24h of control cells)]. Experiments were performed 
in triplicate for each concentration and were repeated 3 times. 
 
2.10. Formation of capillary-like structures 
Analysis of capillary-like structure formation was performed using EAhy 926 endothelial 
cells grown on Matrigel. Fifty µl of the Matrigel solution was applied to each well on a 96-
well plate and incubated for 30 min at 37°C. EAhy 926 cells (1 × 10
4
) were suspended in 100 
µl of medium, plated onto the gel matrix and incubated at 37°C. Adherent cells received 
bFGF (10 ng/ml) and fisetin or geraldol at increasing concentrations (0, 22, 44 and 88 µM). 
After a 24 h exposure time, in vitro angiogenesis was assessed by counting the capillary-like 
structures in each well at X 100 magnification under a light microscope (Zeiss). The in vitro 
anti-angiogenic effect was calculated by the following formula: 100 × [1-(number of 
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capillary-like tube of treated cells) / (number of capillary-like tube of control cells)]. 
Experiments were performed in duplicate for each condition and repeated 3 times. 
 
2.11. Statistical analysis 
Results are expressed as the mean ± SEM of at least 3 independent experiments. Statistical 
differences between means were assessed using the Student t test for unpaired data. If unequal 
variance was observed, the Welch's correction was applied. A P value ≤ 0.05 was considered 
significant. 
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3. Results 
 
3.1. Plasma and tissue pharmacokinetics of fisetin and its metabolites 
 
A representative chromatogram depicting the separation of fisetin and its metabolites in 
mouse plasma is presented in Figure 2. In these chromatographic conditions (reversed-phase 
mode), fisetin eluted at 40 min and the internal standard (kaempferol) at 53 min. Fisetin 
plasma pharmacokinetics after an i.p. administration at a dose of 223 mg/kg is presented in 
Figure 3 and Table 1. The maximum plasma concentration reached 2.53 µg/ml at 15 min post 
dosing and declined thereafter with a first rapid alpha half-life of 0.09 h (5.4 min), followed 
by a longer terminal disposition half-life beta of 3.12 h. The total area under the plasma 
versus time curve (AUC) was 4.0 µg × h/ml, the apparent intraperitoneal clearance (CL/F) 
was 1.12 L/h, and the Vss/F was 5.1 L. 
As shown in Figure 2, in addition to the fisetin peak, several other peaks not present in 
control plasma were also detected. Of those peaks, two metabolites eluted before fisetin (M1 
at 26 min and M2 at 35 min), whereas another metabolite (M3) eluted after fisetin with a 
retention time of 48 min. Figure 4 presents the relative concentrations of these metabolites as 
a function of time using fisetin as a reference. It can be observed that metabolites M1 and M2 
could achieve apparent higher concentrations than the parent compound, whereas metabolite 
M3 apparent concentrations were lower compared to fisetin. Pharmacokinetic parameters of 
the metabolites are presented in Table 1. 
To obtain some information on fisetin and metabolites levels in normal tissues, mice 
were sacrificed 30 minutes after i.p. injection of fisetin and liver, intestines, kidneys, lungs 
and spleen were harvested. Fisetin and metabolites levels presented in Table 2 show that 
fisetin concentrations were highest in liver, intestines and kidneys. Metabolite M1 highest 
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concentrations were mainly found in plasma and kidneys. For metabolites M2 and M3, the 
highest concentrations were in kidneys and intestines. 
 We next submitted plasma samples to β-glucuronidase digestion, and the M1 and M2 
metabolite peaks were completely abolished, whereas the fisetin and the M3 peaks were 
markedly increased as shown in Figure 5 (compare with Fig. 2 without β-glucuronidase). This 
observation indicated that M1 and M2 were glucuronides of fisetin and metabolite M3, 
respectively.  
 
3.2. Identification of metabolite M3 
 
To identify metabolite M3, the peak at 48 min was subjected on line to mass spectrometry 
analysis and UV spectrum determination. The mass spectrum of M3 presented a molecular 
ion m/z value of 301 Da [M+H]
+
, thus corresponding to a molecular weight of 300 Da (Figure 
6-A). In the same conditions, fisetin presented a M+H m/z value of 287 Da corresponding to a 
molecular weight of 286 Da (data not shown). Therefore, the gain of 14 atomic mass units 
observed with M3 over the parent compound corresponded to the addition of a CH2 on the 
fisetin molecule, indicating that metabolite M3 was a methylated compound of fisetin. 
However, because fisetin possesses 4 hydroxyl groups, the exact localization of the methoxyl 
on the fisetin molecule could not easily be identified.  
 
In addition, the UV spectrum of M3 was found superimposable to that of fisetin with identical 
maxima at 245, 320 (shoulder) and 360 nm (Figure 6-B). Among the possible methylated 
fisetin candidates, the 3,4',7-trihydroxy-3'-methoxyflavone or geraldol (cf. Figure 1), 
therefore appeared as a possible candidate. Geraldol UV spectrum was indeed found 
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superimposable to that of M3 and fisetin (Figure 6-B). Also the mass spectrum of authentic 
geraldol was also superimposable to the mass spectrum of M3 (data not shown). 
 
Authentic geraldol was also tested for its HPLC retention time and it was found to co-elute 
with metabolite M3 in 4 different ternary elution systems (Table 3), thus further substantiating 
that M3 was indeed geraldol. In addition, the logarithm of the retention factor (log k) of M3 
and geraldol yielded the same values, further substantiating the identity of M3 as geraldol. 
Considering M3 molecular mass identical to geraldol, its UV spectrum superimposable to 
both fisetin and geraldol spectra, its retention times and log k identical to authentic geraldol in 
4 ternary gradient systems, allowed us to ascribe M3 as being geraldol. 
 
3.3. Tumor concentration of fisetin and its metabolites 
 
At 15 min after the administration of fisetin i.p. (223 mg/kg) to tumor bearing mice (Lewis 
lung carcinoma), the plasma and tumor concentrations of fisetin and its main metabolites were 
also determined by HPLC. Glucuronides M1 and M2 presented higher concentrations in the 
plasma compared to tumors (compare Figures 7A and 7B). However, it was of interest to note 
that geraldol was the metabolite that reached the highest concentrations in tumors (Figure 7-
B). Indeed, geraldol concentrations in tumors were 4.3 times higher than the fisetin 
concentration in this tissue at this sampling time. Considering this observation, we were next 
interested to investigate further the geraldol cytotoxic and antiangiogenic properties.  
 
3.4. Cytotoxic activity of fisetin and geraldol on Lewis lung carcinoma (LLC) cells, 
endothelial cells (EAhy 926), and normal cells (IH 3T3) 
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The effect of fisetin and metabolite geraldol on the viability of Lewis carcinoma cells, 
endothelial cells (EAhy 926), and normal NIH 3T3 cells were also tested (Figure 8). A dose-
dependent decrease in viability of the three cell lines after a 24 h exposure time to both 
flavonoids could be observed. The most cytotoxic flavonoid on LLC cells was found to be 
geraldol with an IC50 (the concentration producing 50 % reduction of viability) of 24 µM, 
about 2.5-fold lower than that of fisetin (59 µM) (Fig. 8-A). Concerning the effect on EAhy 
926 endothelial cells viability, fisetin and geraldol showed similar IC50 (76 and 72 µM, 
respectively) (Fig. 8-B). However, it was of interest that the normal NIH 3T3 cells were 
significantly less sensitive to fisetin and geraldol than either LLC or endothelial cells, with 
IC50 of 195 µM and 128 µM, respectively (Fig. 8-C). 
 
3.5. Fisetin and geraldol effect on endothelial cells migration in vitro 
 
We next compared the effect of various concentrations (22, 44, 88 µM) of fisetin and its 
metabolite geraldol on EAhy 926 endothelial cells migration using the scrape wound assay. 
Figure 9 illustrates that at 24 h post-wounding of confluent EAhy 926 endothelial cells, the 
control bFGF (10 ng/ml) treated cells migrated and totally filled the scraped area, as expected. 
Although fisetin and geraldol could inhibit significantly endothelial cells migration at 44 µM 
(Figure 9), fisetin was found more active than geraldol at this concentration, and also at the 
lower concentration of 22 µM (Figure 10). Although the inhibition of endothelial cells 
migration was dose-dependent for both flavonoids, the calculated IC50 for the antimigration 
effect showed that fisetin had a significantly (p<0.001) stronger antimigration effect 
compared to geraldol (43 ± 0.8 µM versus 64 ± 0.8 µM, respectively)
 
(Figure 10).  
 
3.6. Fisetin and geraldol effect on the capillary-like structure formation on Matrigel 
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To examine whether geraldol could directly inhibit angiogenesis, its effect on bFGF-mediated 
tube formation by endothelial cells was investigated at concentrations ranging from 3 to 300 
µM. As expected, EAhy 926 endothelial cells plated on Matrigel with bFGF (10 ng/ml) 
formed a capillary-like network within 24 h (data not shown). Fisetin could prevent the 
formation of the capillary-like network in a dose-dependent fashion with an IC50 of 51 ± 7 
µM, whereas no significant antiangiogenic effect of geraldol could be observed at the highest 
achievable in vitro concentration of 88 µM, because geraldol was not soluble at higher 
concentrations (data not shown). 
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4. Discussion 
The natural flavonoids are attracting interest in cancer prevention and therapy because 
these compounds are relatively non toxic compared to other chemotherapeutic agents used in 
cancer therapy [1-4]. Although the dietary flavonoid fisetin has recently been shown to be an 
interesting anticancer active agent in mice [7-9] and to possess antiangiogenic properties in 
vitro [12;13] and in vivo [9], the blood levels achieved by this compound after systemic 
administration and its metabolism have not previously been investigated in mice. The purpose 
of this study was therefore to study fisetin pharmacokinetics in mice, to determine fisetin 
principal metabolic routes and to evaluate the biological activity of a detected metabolite. 
 Concerning the pharmacokinetics of fisetin in mouse plasma, we found that it could 
reach a concentration of 2.5 µg/ml at 15 min and that it displayed a relatively long terminal 
half-life in plasma of 3.12 h after an i.p. administration of 223 mg/kg. Although the plasma 
concentrations are relatively low, it is possible that the long residence time could be 
responsible for the remarkable in vivo antitumor effect in mice at this dose level [9]. 
Nonlinear pharmacokinetics may also be involved in the fisetin long residence time at this 
dose level, as nonlinear pharmacokinetics has already been reported for other flavonoids [30]. 
Potential accumulation of fisetin and/or metabolites in tumour tissue could also play a role in 
the fisetin antitumour activity. Compared to fisetin pharmacokinetics in rat in which 
negligible levels of free fisetin and a short half-life of 2.7 minutes were reported [31], it thus 
appears that the mouse is eliminating fisetin at a much slower rate (half-life = 3.12 hours), 
probably due to a lower conjugation capacity through glucuronidation in mice. Indeed, such 
significant species differences in clearance has also been observed for the flavonoid analogue 
5,6-dimethylxanthenone-4-acetic acid (DMXAA), which is also mainly metabolized through 
glucuronidation, where in vitro intrinsic clearance in mice was found to be 15-fold lower that 
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in rats, and in vivo plasma clearance was 1.8-fold smaller in mice compared to rat plasma 
clearance [32].  
We also observed that metabolites M1 and M2, which were identified as glucuronides, 
displayed longer terminal half-lives compared to fisetin. This appears unusual since these two 
metabolites are glucuronides of fisetin and M3, and shorter half-lives could have been 
expected. However such a pharmacokinetic behaviour has also been reported for fisetin in rats 
where a half-life of 2.7 min was found for the aglycone, whereas the glucuronides were 
showing a half-life of 40.7 min [31]. Such a longer half-life for genistein 
sulfates/glucuronides has also been observed in rats compared to the parent aglycone [33].  
 In this study, we have also identified a methylated metabolite of fisetin which was 
assigned to the 3,4',7-trihydroxy-3'-methoxyflavone (geraldol). This metabolite, reported here 
for the first time to our knowledge, is probably generated through catechol-O-methyl 
transferase (COMT) metabolism because fisetin possesses a catechol function on the B ring. 
COMT catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to polyphenols 
possessing an o-diphenolic (catechol) moiety. COMT can be found as membrane bound and 
soluble forms and is expressed in brain and most peripheral tissues including liver, kidneys 
and small intestine in the mouse, although there are large differences between species [34;35]. 
Methylation has already been reported for other flavonoids possessing a catechol function, 
e.g., quercetin, catechin, caffeic acid, and luteolin (reviewed in [35]). Methylation of 
flavonoids generally occurs predominantly in the 3'-position of the polyphenol, but a minor 
proportion of 4'-O-methylated product can also be formed.  
Although our mass spectrometry data indicated the presence of a methoxyl group on the 
fisetin molecule, the exact position of this substituent could not be determined by this 
technique alone. The formal identification of the methoxylated metabolite of fisetin was 
therefore further investigated using UV spectroscopy which is particularly useful for the 
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identification of flavonoids [36]. It is known that methylation of hydroxyl groups in positions 
3, 5, 7, or 4’ produces hypsochromic shifts (shorter wavelengths) of the characteristic 
absorption bands in the UV-spectra of flavones, but does not significantly affect the shape of 
the UV-spectra when it occurs in other positions [37]. In our case, metabolite M3 did not 
present a hypsochromic shift compared to the parent compound and their UV spectra were 
superimposable. Therefore, the methylation of the 3, 4’, and the 7 positions could therefore be 
ruled out as possible methylated positions of fisetin.  
We further ascertained the identity of metabolite M3 as being the 3,4’,7-trihydroxy-3’-
methoxyflavone or geraldol using the log k value obtained by reversed-phase HPLC. It was 
already demonstrated that log k values are significantly different for the same flavone if 
methylated in the 3’ or the 4’ position [28]. Using the same approach, the log k values 
obtained with 4 different ternary mobile phases were strictly identical for geraldol and 
metabolite M3, therefore substantiating further that M3 was indeed the 3’-methyl-fisetin, and 
could not be the 4’-methyl-fisetin. Concerning the possible methylation on position 3 of 
fisetin, this would have resulted in a decrease in the retention time in the reversed-phase 
HPLC mode, owing to its inductive effect which increases the influence of the polar carbonyl 
group [28]. Methylation of the hydroxyl group in position 3 results in a lack of hydrogen 
bonding between 3-OH and the carbonyl group (at C4) which results in an increased polarity 
of the molecule and consequently a decreased in retention time. In contrast, an increase in 
retention time was observed compared to fisetin, which further rules out a methylation at the 3 
position of fisetin. Considering metabolite M3 molecular mass M3 identical to geraldol, its 
UV spectrum identical to fisetin and geraldol, and identical retention times to geraldol in 4 
different ternary gradient systems, the identity of M3 was therefore assigned to geraldol.  
Of particular interest, it was also observed that this 3’-methoxylated metabolite of fisetin 
could achieve higher concentrations in tumors compared to fisetin, an observation probably 
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linked to the fisetin in vivo remarkable anticancer activity already noted by some investigators 
[7-9]. This high tumor geraldol levels could result from either an increased in situ formation 
or this metabolite, or from hydrolysis of its glucuronide that could regenerate the aglycone. 
Indeed, a high COMT activity in the tumor is possible because an increased expression of this 
enzyme has recently been observed in cancer [38]. Concerning the possible regeneration of 
the aglycone from its corresponding glucuronide, it has been reported that Lewis lung tumors 
express a high β-glucuronidase activity that could hydrolyze the glucuronide to its geraldol 
aglycone [39].  
From a metabolic standpoint, the methylation of fisetin in vivo could be viewed as a 
favourable metabolic route, because methylation usually results in a higher metabolic stability 
of flavonoids that could favour its retention in vivo [40]. Because geraldol can be 
glucuronidated, as shown in this work, and could therefore be secreted in bile, bacterial 
glucuronidase present in the intestines could hydrolyze this metabolite and give back the 
aglycone (geraldol) that could be absorbed from the intestines, therefore possibly contributing 
to a longer residence time in vivo for this metabolite. In addition, the presence of a methoxy 
group on the A or B ring of the flavonoid also seems to protect the structure from bacterial 
degradation in faeces, therefore probably contributing to longer exposure times in vivo by 
allowing the reabsorption from the intestines of the intact methylated metabolite [41].  
However, we observed in this work that the geraldol formed in vivo is rapidly cleared 
from the plasma as shown by its short half-life, although this metabolite is less polar and 
probably more metabolically stable than fisetin. We have no obvious explanation for this 
observation, except that upon geraldol formation in vivo, this metabolite could be rapidly 
metabolized to other metabolites (e.g., glucuronides and/or sulfates), which could perhaps 
explain its rapid clearance.  
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The fisetin antiproliferative/cytotoxic activity determined in this study on Lewis lung 
carcinoma cells is in line with its cytotoxic activity reported on other cancer cell lines, e.g., in 
prostate [17], liver [16], colon [18], and leukemia cell lines [14]. With regard to the 
comparison of the biological activity of fisetin and its metabolite geraldol, it was of interest to 
note that the metabolite was more cytotoxic than the parent compound on Lewis lung 
carcinoma cells showing a 2.5-fold lower IC50 value. This increased cytotoxicity of the 
metabolite associated with the higher concentrations of geraldol in tumor could give fisetin a 
selective anticancer activity advantage in vivo. Also of interest, both fisetin and geraldol were 
found several folds less cytotoxic towards normal NIH 3T3 cells compared to tumor cells, and 
this could give these compounds an important in vivo advantage in terms of therapeutic index, 
because they would be less toxic to normal cells compared to cancer cells. This relative non 
toxicity of flavonoids to normal cells was also noted for other normal cell lines [13]. This 
tumor cell selectivity was also observed on prostate cancer cells that were shown to be more 
vulnerable to fisetin compared to normal prostate cells [17]. This relatively uncommon cancer 
cell selectivity could therefore confer fisetin a valuable advantage for in vivo anticancer 
treatment.  
In addition, it should be mentioned that because of the presence of 4 hydroxyl substituents 
on the fisetin molecule, several glucuronide conjugates were also detected at high 
concentrations in mouse plasma in the present mouse study, and also in rat plasma [31]. These 
metabolites could also play a role in the overall antiangiogenic effects observed in vivo in 
mice, because some flavonoid sulfates and/or glucuronides have been reported to display 
bioactivities sometimes superior to their aglycones (free forms) [42-45]. Future studies aimed 
at determining potential high partition of metabolites and/or accumulation in tumour tissue 
should also be considered, as well as a more complete pharmacokinetic profile of fisetin and 
its metabolites in tumours should also be assessed. 
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The interesting bioactivity of geraldol shown in the present work has also to be put in 
perspective of a recently published work on quercetin (3’,3,4’,5,7-pentahydroxyflavone), a 
close parent of fisetin bearing an additional 5-hydroxyl substituent. A 3’-O-methylated 
metabolite of quercetin, i.e., isorhamnetin, was shown to possess potent inhibitory activity of 
cyclo-oxygenase-2 (COX-2), an enzyme mechanistically linked to carcinogenesis [46]. Also 
in line with this observation, quercetin metabolites have been found to possess antioxidant 
properties [47-49], and to inhibit xanthine oxidase and lipoxygenase [50].  
Regarding the effect of fisetin and geraldol on the formation of capillary-like structures, 
the parent compound fisetin has previously been shown to be active in this model [9], whereas 
geraldol could not achieve an active concentration in this model probably due to its inherently 
low water solubility. It is however possible that longer exposure time to geraldol (> 24 h) 
could nonetheless participate to an antiangiogenic response in vitro. Considering the above 
results, it is therefore possible that fisetin antitumor action in vivo could involve a dual 
mechanism of action, i.e., the parent compound fisetin would exert its strong antiangiogenic 
action directly, whereas its main metabolite geraldol would then exert its strong cytotoxicity 
against tumor cells. 
In conclusion, we have determined fisetin pharmacokinetics in mice, for the first time to 
our knowledge, and have also identified geraldol, a previously unknown metabolite. In 
addition, we have shown that the metabolite geraldol possesses interesting biological 
activities in terms of selective cytotoxicity on cancer cells, antiproliferative and antimigration 
effects on endothelial cells. Fisetin and geraldol anticancer and antiangiogenic properties 
therefore deserve to be optimized in preclinical models, as a single administration or in 
combination therapy with cytotoxic anticancer agents. 
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Table 1. Fisetin and metabolites pharmacokinetic parameters.
1 
 Cmax (µg/ml) AUC (µg/ml)×h MRT (h) Half-lives (h) 
Fisetin 2.53 4.00 4.51 3.12 
Metabolite M1 6.54 40.71 11.27 7.81 
Metabolite M2 2.22 13.63 9.95 6.89 
Metabolite M3 0.07 0.17 0.65 0.45 
1 
Cmax, maximum plasma concentration; AUC, area under the plasma concentration versus 
time curve from time zero to the time of the last measurable concentration; MRT, mean 
residence time.  
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Table 2. Fisetin and its metabolites distribution in plasma and normal tissues in mice. 
Mice were administered fisetin intraperitoneally at a dose of 223 mg/kg and tissues were 
harvested 30 minutes later for HPLC analyses, as detailed in the Materials and Methods 
section. Values are the mean ± SEM of 3 independent determinations.  
 
 Concentration (µg/ml or µg/g tissue) 
Tissues Fisetin M1 M2 M3 
Plasma 1.14 ± 0.12 6.12 ± 0.47 1.93 ± 0.29 0.10 ± 0.01 
Liver 39.15 ± 12.85 0.66 ± 0.22 2.02 ± 1.31 2.23 ± 0.38 
Intestines 80.11 ± 33.82 0.12 ± 0.08 4.17 ± 3.24 5.05 ± 0.49 
Kidneys 83.69 ± 10.45 4.23 ± 1.88 49.03 ± 22.65 14.25 ± 6.54 
Lungs 8.00 ± 3.31 0.69 ± 0.46 5.67 ± 5.69 1.57 ± 0.67 
Spleen 2.00 ± 0.50 1.03 ± 1.37 1.30 ± 1.01 1.71 ± 1.67 
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Table 3. Retention times of fisetin and geraldol in various HPLC ternary gradient 
systems 
Gradient    Retention times in minutes (log k)
 b
   
  system 
a
  Fisetin    Geraldol  Metabolite M3 
1  40.0 (0.561)  47.7 (0.590)  47.7 (0.591) 
2  49.4 (0.596)  60.1 (0.628)  60.1 (0.628) 
3  28.6 (0.504)  39.0 (0.557)  39.0 (0.557) 
4  32.8 (0.528)  46.6 (0.586)  46.6 (0.586) 
 
a
 The ternary gradient systems used were composed of methanol (A), acetonitrile (B) and 
water containing 0.1% TFA, as follows: gradient 1- from 0 to 50 min: 7-35% A, 4-19% B, 89-
46% C ; gradient 2- from 0 to 70 min: 7-35% A ; 4-19% B ; 89-46% C ; gradient 3- from 0 to 
50 min : 15-35% A ; 10-19% B ; 75-46% C ; gradient 4- from 0 to 70 min : 15-35% A ; 10-
19% B ; 75-46% C. The reversed-phase HPLC system used is described in the Methods 
section. 
b
 The retention factor k was calculated as in Stefova et al., 2007 [27] 
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Legends for Figures 
Figure 1. Chemical structures of fisetin, geraldol and kaempferol. R1=OH, R2=H, fisetin 
or 3,3’,4’,7-tetrahydroxyflavone; R1 = OCH3, R2=H, geraldol or 3,4’,7-trihydroxy-3’-
methoxyflavone; R1 = H, R2 = OH, kaempferol or 3,4’,5,7-tetrahydroxyflavone. 
Figure 2. Representative HPLC chromatogram showing the separation of fisetin and its main 
metabolites formed in vivo (M1, M2, M3) 15 minutes after the intraperitoneal injection of 
fisetin at a dose of 223 mg/kg. Kaempferol was used as an internal standard. In control 
plasma, there was no detectable peak present after the first 5 minutes.  
Figure 3. Pharmacokinetic profile of fisetin in mouse plasma. After an intraperitoneal 
injection of 223 mg/kg, fisetin concentration was determined by HPLC as described in 
Materials and Methods. Mean ± SEM of 3 mice per time point. Solid line represents the 
fitting to an extravascular 2 compartment model. 
Figure 4. Plasma concentration of the main fisetin metabolites (M1, M2 and M3) as a 
function of time after the intraperitoneal injection of fisetin (223 mg/kg). Fisetin and 
metabolites concentrations were determined by HPLC as described in Materials and Methods. 
The apparent concentration of the metabolites was calculated based on the fisetin standard 
curve. Mean ± SEM of 3 mice per time point. Solid squares, fisetin; triangles, metabolite M1; 
circles, metabolite M2; diamonds, metabolite M3. 
Figure 5. Representative HPLC chromatogram showing the beta-glucuronidase digestion of 
Metabolites M1 and M2 to yield fisetin and metabolite M3. Mice received an intraperitoneal 
injection of fisetin at a dose of 223 mg/kg. Kaempferol was used as an internal standard.  
Figure 6. Mass and UV spectra of metabolite M3. A) Representative mass spectrum of 
metabolite M3 obtained on line with an HPLC MS/MS equipment detailed in Materials and 
Methods. B) UV spectra of fisetin, metabolite M3, and geraldol obtained online using a diode 
array detector. 
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Figure 7. A) Plasma and B) tumor concentrations of fisetin and its main metabolites M1, M2 
and M3 (geraldol), 15 min after the i.p. administration of fisetin (223 mg/kg). M1 and M2 are 
glucuronides of fisetin and geraldol, respectively, whereas M3 is geraldol. Concentrations 
were determined by HPLC as described in the Materials and Methods. 
Figure 8. Comparative cytotoxicity of fisetin and geraldol on various cell lines. 
Figure 9. Effect of fisetin and its metabolite geraldol on endothelial cell migration (scratch 
wound assay). Confluent EAhy 926 endothelial cells were grown to confluence and an area 
was cleared using a 100 µl pipet tip. Digital photographs were recorded at a magnification of 
X 100 at time 0 and 24 hours later after the addition of bFGF (10 ng/ml) for the control, or 
with bFGF plus 44 µM of either fisetin or geraldol. Scale bar, 40 µm. 
Figure 10. Comparative antimigration effects of fisetin and its metabolite geraldol. 
Endothelial EAhy 926 cells were grown to confluence and cell wounding was induced using a 
pipet tip, as described in Materials and Methods. After a 24 h exposure time at the indicated 
concentrations of fisetin (hatched bars) and geraldol (open bars) in presence of bFGF, the 
relative antimigration effect was calculated as described in Materials and Methods. Mean ± 
SEM of 3 independent experiments. Asterisks indicate a statistically significant difference 
relative to controls at the P<0.05 (*) or P<0.001 (***) level (Student t test). 
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